Venom peptides targeting the KV1.3 potassium channel — critical for T cell activation in autoimmune diseases — represent a growing class of selective immunosuppressants with potential advantages over current drugs.
Selective immunosuppressionKV1.3-targeting venom peptides suppress only the specific T cells driving autoimmune disease, potentially avoiding the broad immune suppression of current drugs
What the researchers found
KV1.3 ion channel inhibitors derived from venom peptides selectively suppress effector memory T cells involved in autoimmune diseases, with multiple medicinal chemistry approaches being pursued to optimize them as therapeutics.
Why it matters
Current immunosuppressants have broad side effects. KV1.3-selective peptides could suppress autoimmune T cells specifically without the wide immunosuppression of current drugs like cyclosporine or methotrexate.
The numbers in context
ShK-186 (dalatazide) in clinical trials; targets KV1.3 selectively; derived from sea anemone ShK toxin; applications in MS, T1D, psoriasis, RA, cancer
How the study worked
Narrative review of KV1.3 biology, venom-derived peptide inhibitors, and medicinal chemistry strategies for drug optimization.
Who was studied
Review covering preclinical through clinical research on KV1.3 inhibitors
What this study cannot tell us
Review of mostly preclinical data. No KV1.3 peptide drugs have completed clinical trials for autoimmune diseases. Selectivity between KV1.3 and related channels remains challenging. Peptide delivery and half-life are practical hurdles.
How to read the evidence
Not applicable (narrative review). Based on preclinical pharmacology and medicinal chemistry data.
When this study was published
Published 2021. KV1.3 channel targeting for autoimmune disease continues in preclinical and early clinical development.
The bigger picture
KV1.3 blocking peptides represent a shift from broad immunosuppression to targeted immune modulation. As the most advanced venom-derived ion channel therapeutics, they could transform autoimmune disease treatment if selectivity and delivery challenges are solved.
Questions still open
- Which KV1.3 peptide inhibitor is closest to clinical trials for autoimmune disease?
- Can KV1.3 blockers be made orally bioavailable?
- Would KV1.3 inhibition be safer than current immunosuppressants for long-term autoimmune therapy?
Common questions
What is KV1.3 and why target it?
Are there any KV1.3 drugs available?
Read the original research
Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.
Medicinal research reviews, 41(4), 2423-2473
Citation
Gubič, Špela; Hendrickx, Louise A; Toplak, Žan; Sterle, Maša; Peigneur, Steve; Tomašič, Tihomir; Pardo, Luis A; Tytgat, Jan; Zega, Anamarija; Mašič, Lucija P. (2021). Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.. Medicinal research reviews, 41(4), 2423-2473. https://doi.org/10.1002/med.21800